High-THC cannabis flower linked to improvements in quality of life

  • HOME
  • /
  • News
  • /
  • High-THC cannabis flower linked to improvements in quality of life

High-THC cannabis flower linked to improvements in quality of life
29-Oct-22 05:06:31

UK patients reported improvements in overall quality of life, pain severity and symptoms of anxiety.

The inhalation of THC-predominant cannabis flower improves quality of life and symptoms of chronic pain and anxiety in UK patients, finds a new study.

In a new paper, published using data from the UK observational study Project Twenty21 (T21) patients report ‘significant improvements’ in health-related quality of life when prescribed a THC-predominant cannabis flower produced by Khiron Life Sciences.

Inhalation of Khiron 20:1, which contains 20% THC to 1% CBD, was also shown to improve general mood and sleep, as well as pain severity and symptoms of anxiety.

Khiron 20:1 is thought to be one of the most commonly-prescribed products in the T21 formulary.

An overview of the study

In November 2018, the UK’s Home Office established a legal route for eligible patients to be prescribed cannabis based products for medicinal use in humans (CBPMs) as unlicensed medicines. These include liquid cannabis extracts for oral administration (‘oils’) and dried flowers for inhalation (‘flos’). Smoking of CBPMs is expressly prohibited.

To date, THC-predominant cannabis flowers remain the most prescribed CBPMs in Project Twenty21 (T21), the first multi-centre, prospective, observational UK cannabis patient registry.

This observational, prospective data review analyses patient-reported outcome measures (PROMS) collected by T21 associated with the inhalation of the product, Khiron 20:1, the most prescribed CBPM in the project.

PROMS collected at baseline and at subsequent three-month follow-up included health-related quality of life (HRQoL), general mood, and sleep. Condition-specific measures of illness severity were performed with the Brief Pain Inventory Short Form (BPI-SF) and the Generalised Anxiety Disorder 7-Item Scale (GAD-7).

The findings

Participants were mostly males  (77.6%, average age = 38.3) diagnosed mainly with chronic pain (50.9%) and anxiety-related disorders (25.3%)

Inhalation of Khiron 20:1 was associated with a marked increase in self-reported HRQoL, general mood, and sleep. Condition-specific assessments showed significant improvements in pain severity and interference in patients using Khiron 20:1 for chronic pain.


The authors concluded: “Our results indicate that controlled inhalation of pharmaceutical grade, THC-predominant cannabis flos, Khiron 20:1 is associated with a significant improvement in patient-reported pain scores, mood, anxiety, sleep disturbances and overall HRQoL in a treatment-resistant clinical population.”